Posts Tagged ‘PDAB’
Prescription Drug Affordability Board Activity through December 18, 2024
Prescription Drug Affordability Board Activity through December 18, 2024 Activities Summary Colorado: The Prescription Drug Affordability Board (PDAB) met on December 6, 2024 to hear and discuss public comment before proposing and approving revisions to policy and procedures around affordability reviews. The PDAB updated the state’s Prescription Drug Affordability Review Board and Advisory Council (PDAAC)…
[...]Prescription Drug Affordability Board Activity through November 15, 2024
Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.
[...]Prescription Drug Affordability Board Activity through October 18, 2024
Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.
[...]Prescription Drug Affordability Board Activity through August 15, 2024
Colorado clarifies who their Upper Payment Limit rule applies to. Maryland picks six drugs to conduct cost reviews for and requests information from the public in an effort to produce something by year end. Oregon pauses affordability reviews for 2024 while it gathers feedback from stakeholders. Washington considers the eligibility criteria for drugs to be reviewed, looking to states like Colorado for guidance.
[...]PSM testimony: Colorado Prescription Drug Affordability Board Meeting, June 7, 2024
A Colorado board is considering setting a price limit on the medicine Stelara. This will have unintended consequences, undermining the safety of the supply chain for this medicine and limiting patient access. Learn more by reading our testimony.
[...]How Upper Payment Limits on medicine increase the risk of diverted and counterfeit medicine in the drug supply
States like Colorado are experimenting with Prescription Drug Affordability Boards to address the price of medicine, but solutions like Upper Payment Limits will yield multiple unintended consequences that will do more harm than good to patients.
[...]